Patents by Inventor Luca Claudio Gobbi
Luca Claudio Gobbi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7795437Abstract: The present invention relates to ether derivatives according to general formula I, and to their pharmaceutically-acceptable salts, which may be used in treating or preventing cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, or psychoses comprising paranoia and delusions.Type: GrantFiled: October 22, 2007Date of Patent: September 14, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Luca Claudio Gobbi, Georg Jaeschke, Olivier Roche, Rosa Maria Rodriguez Sarmiento, Lucinda Steward
-
Patent number: 7790732Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3 are as described in the specification and pharmaceutically acceptable acid addition salts and tautomers thereof. Compounds of formula I have good activity on the 5-HT5A receptor. Therefore, the invention provides a method for treating diseases related to this receptor, for example, anxiety, depression, sleep disorders and schizophrenia.Type: GrantFiled: June 21, 2006Date of Patent: September 7, 2010Assignee: Hoffman-La Roche Inc.Inventors: Alexander Alanine, Luca Claudio Gobbi, Sabine Kolczewski, Thomas Luebbers, Jens-Uwe Peters, Lucinda Steward
-
Patent number: 7790733Abstract: The present invention relates to compounds of formula wherein R1, R2, R3, and n are as described in the specification and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I can be used for the treatment of 5-HT5A receptor antagonists related diseases, which include depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, disorders of eating behaviors, sexual dysfunction, sleep disorders, withdrawal from abuse of drugs, motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders and gastrointestinal disorders such as irritable bowel syndrome.Type: GrantFiled: June 21, 2006Date of Patent: September 7, 2010Assignee: Hoffman-La Roche Inc.Inventors: Alexander Alanine, Luca Claudio Gobbi, Sabine Kolczewski, Thomas Luebbers, Jens-Uwe Peters, Lucinda Steward
-
Patent number: 7781441Abstract: The present invention relates to compounds of formula I wherein R, R1, R2, R3, R4, aryl, n, and m are as defined in the specification and pharmaceutically acceptable acid addition salts and tautomeric forms thereof. Such compounds have good activity on the 5-HT5A receptor. Therefore, the invention provides methods for the treatment of certain CNS disorders with such compounds.Type: GrantFiled: April 27, 2006Date of Patent: August 24, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Alanine, Luca Claudio Gobbi, Sabine Kolczewski, Thomas Luebbers, Jens-Uwe Peters, Lucinda Steward
-
Patent number: 7459480Abstract: This invention relates to compounds of the formula wherein B, X, Y, Z, R1 and R2 are as defined in the description, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by ACC? inhibitors.Type: GrantFiled: October 29, 2004Date of Patent: December 2, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Luca Claudio Gobbi, Marcel Gubler, Werner Neidhart, Matthias Heinrich Nettekoven
-
Patent number: 7368454Abstract: The present invention relates to methods for treating 5-HT5A receptor related diseases which comprises administering compounds of formula I wherein R1, R2, aryl, and n are defined in the specification and pharmaceutically acceptable acid addition salts thereof.Type: GrantFiled: March 8, 2006Date of Patent: May 6, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Alanine, Luca Claudio Gobbi, Sabine Kolczewski, Thomas Luebbers, Jens-Uwe Peters, Lucinda Steward
-
Patent number: 7348332Abstract: The present invention relates to compounds of formula wherein R1, R2, and n are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I have a good activity on the 5-HT5A receptor. Therefore, the invention provides the use of a compound of formula I for 5-HT5A receptor related diseases, such as anxiety, depression, sleep disorders and schizophrenia.Type: GrantFiled: April 5, 2006Date of Patent: March 25, 2008Assignee: Hoffmann-La Rochse Inc.Inventors: Alexander Alanine, Luca Claudio Gobbi, Sabine Kolczewski, Thomas Luebbers, Jens-Uwe Peters, Lucinda Steward
-
Patent number: 7268154Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the specification and to pharmaceutically suitable acid addition salts thereof. The invention includes all sterioisomeric forms, including individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. It has been found that the present compounds are selective allosteric positive modulators of the human NK-3 receptor for the treatment of anxiety, depression, bipolar disorders, Parkinson's disease, schizophrenia and pain.Type: GrantFiled: July 18, 2006Date of Patent: September 11, 2007Assignee: Hoffman-La Roche Inc.Inventors: Luca Claudio Gobbi, Marius Hoener, Claus Riemer, Will Spooren
-
Patent number: 7129238Abstract: The invention is concerned with novel mandelic acid derivatives of formula (I) wherein R1 to R10, X and Y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit the formation of coagulation factors Xa, IXa and thrombin induced by factor VIIa and tissue factor.Type: GrantFiled: November 21, 2003Date of Patent: October 31, 2006Assignee: Hoffmann-La Roche Inc.Inventors: David William Banner, Luca Claudio Gobbi, Katrin Groebke Zbinden, Ulrike Obst, Christoph Martin Stahl
-
Patent number: 7056932Abstract: The invention is concerned with novel heterocyclyl substituted 1-alkoxy acetic acid derivatives of formula (I) wherein R1 to R6 and A are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the formation of coagulation factors Xa, IXa and thrombin induced by factor VIIa and tissue factor and can be used as medicaments.Type: GrantFiled: December 10, 2004Date of Patent: June 6, 2006Assignee: Hoffman-La Roche Inc.Inventors: Luca Claudio Gobbi, Katrin Groebke Zbinden, Peter Mohr, Ulrike Obst
-
Patent number: 6897222Abstract: The present invention provides compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: March 15, 2004Date of Patent: May 24, 2005Assignee: Hoffmann-La Roche Inc.Inventors: Luca Claudio Gobbi, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Pierre Charles Wyss
-
Publication number: 20040176406Abstract: The present invention provides compounds of formula (I) 1Type: ApplicationFiled: March 15, 2004Publication date: September 9, 2004Inventors: Luca Claudio Gobbi, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Pierre Charles Wyss
-
Publication number: 20040122057Abstract: The invention is concerned with novel mandelic acid derivatives of formula (I) 1Type: ApplicationFiled: November 21, 2003Publication date: June 24, 2004Inventors: David William Banner, Luca Claudio Gobbi, Katrin Groebke Zbinden, Ulrike Obst, Christoph Martin Stahl
-
Patent number: 6727261Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: December 17, 2002Date of Patent: April 27, 2004Assignee: Hoffman-La Roche Inc.Inventors: Luca Claudio Gobbi, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Pierre Charles Wyss
-
Publication number: 20030149071Abstract: The present invention provides compounds of formula (I) 1Type: ApplicationFiled: December 17, 2002Publication date: August 7, 2003Inventors: Luca Claudio Gobbi, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Pierre Charles Wyss